Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD

Mohamed, Adel; Yıldız-Peköz, Ayca; Ross, Kehinde; Hutcheon, Gillian A.

doi:10.1016/j.ijpharm.2019.118524

Cited by 44 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR146a delivered as miR-146a-NPs reduced the IRAK1 expression to 40% and dampened the IL-8 promoter-reporter output. These results demonstrate the potential of PGA-co-PDL NPs as a delivery system for miR-146a to treat COPD [ 122 ]. By transforming polymer nanoparticles into microparticles via spray drying, researchers have demonstrated the potential of transforming polymer nanoparticles into industrial preparations.…”

Section: Introductionmentioning

confidence: 76%

“…Mohamed et al prepared NCMPs of microRNA (miR-146a) containing PGA-co-PDL nanoparticles for dry powder inhalation using l -leucine and mannitol as excipients. The microparticles maintained the bioactivity of miR-146a; however, after dispersion, the nanoparticles size increased, from 244.8 ± 4.40 nm to 409.7 ± 10.05 nm [ 122 ]. The microparticles showed a high FPF of 51.33% and MMAD ≤ 5 µm suggesting that deposition in the respirable region of the lungs would be possible.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Song

2020

J Nanobiotechnol

View full text Add to dashboard Cite

Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.

show abstract

Section: Introductionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Song

2020

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Similarly, pulmonary delivery of nanocomposite microparticles (NCMPs) i.e. PGA-co-PDL nanoparticles with microRNA (miR-146a) by dry powder inhalation was useful for the treatment and management of chronic obstructive pulmonary disease (COPD) [242]. The activity of miR-146a was preserved after the spray-drying process and miR-146a loaded NCMPs were used to silence the target genes IRAK1 and TRAF6.…”

Section: Different Administration Routes Of Nanocarriersmentioning

confidence: 99%

Therapeutic efficacy of nanoparticles and routes of administration

et al. 2019

View full text Add to dashboard Cite

In modern-day medicine, nanotechnology and nanoparticles are some of the indispensable tools in disease monitoring and therapy. The term “nanomaterials” describes materials with nanoscale dimensions (< 100 nm) and are broadly classified into natural and synthetic nanomaterials. However, “engineered” nanomaterials have received significant attention due to their versatility. Although enormous strides have been made in research and development in the field of nanotechnology, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic molecules. Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy. One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization. Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug solubility and bioavailability are discussed. Additionally, different routes of nanocarrier administration are discussed to provide greater understanding of the biological and other barriers and their impact on drug transport. The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges associated with each drug delivery method.

show abstract

“…Since there is a strong correlation between distinct miRNA signature patterns and disease progression in COPD, miRNA profiling has been studied widely. In one study, miR-146a incorporated with NCMPs (nanocomposite microparticles) was successfully delivered to reduce IRAK1 ( IL-1 receptor-associated kinase ) and TRAF6 ( TNF receptor-associated factor 6 ) gene expressions for COPD treatment purposes [ 166 ]. Cadmium, one of the components of cigarette smoke, is known to trigger inflammation and contribute to COPD pathogenesis.…”

Section: Conventional Medications and New Strategies For Ipf And Copdmentioning

confidence: 99%

Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?

Avci

Sarvari

Savai

et al. 2022

IJMS

View full text Add to dashboard Cite

Epigenetic responses due to environmental changes alter chromatin structure, which in turn modifies the phenotype, gene expression profile, and activity of each cell type that has a role in the pathophysiology of a disease. Pulmonary diseases are one of the major causes of death in the world, including lung cancer, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH), lung tuberculosis, pulmonary embolism, and asthma. Several lines of evidence indicate that epigenetic modifications may be one of the main factors to explain the increasing incidence and prevalence of lung diseases including IPF and COPD. Interestingly, isolated fibroblasts and smooth muscle cells from patients with pulmonary diseases such as IPF and PH that were cultured ex vivo maintained the disease phenotype. The cells often show a hyper-proliferative, apoptosis-resistant phenotype with increased expression of extracellular matrix (ECM) and activated focal adhesions suggesting the presence of an epigenetically imprinted phenotype. Moreover, many abnormalities observed in molecular processes in IPF patients are shown to be epigenetically regulated, such as innate immunity, cellular senescence, and apoptotic cell death. DNA methylation, histone modification, and microRNA regulation constitute the most common epigenetic modification mechanisms.

show abstract

Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD

Cited by 44 publications

References 68 publications

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Therapeutic efficacy of nanoparticles and routes of administration

Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?

Contact Info

Product

Resources

About